Published in Rheumatology (Oxford) on April 21, 2006
Rituximab in children with resistant idiopathic nephrotic syndrome. J Am Soc Nephrol (2012) 1.83
Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol (2010) 1.83
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
ANCA-associated vasculitides--advances in pathogenesis and treatment. Nat Rev Rheumatol (2010) 1.67
Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol (2011) 1.62
Bench-to-bedside review: pulmonary-renal syndromes--an update for the intensivist. Crit Care (2007) 1.10
Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide. Clin Rheumatol (2007) 1.08
Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab. Clin Endocrinol (Oxf) (2011) 1.04
The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int (2007) 0.98
Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease. Graefes Arch Clin Exp Ophthalmol (2010) 0.88
Effectiveness of rituximab in severe Wegener's granulomatosis: report of two cases and review of the literature. Open Respir Med J (2009) 0.87
B cell-targeted therapy with anti-CD20 monoclonal antibody in a mouse model of Graves' hyperthyroidism. Clin Exp Immunol (2011) 0.86
Chapter 13: Pauci-immune focal and segmental necrotizing glomerulonephritis. Kidney Int Suppl (2011) (2012) 0.86
Advances in the use of biologic agents for the treatment of systemic vasculitis. Curr Opin Rheumatol (2009) 0.84
Long-term follow-up of different refractory systemic vasculitides treated with rituximab. Clin Rheumatol (2011) 0.83
Indications of rituximab in autoimmune diseases. Drug Discov Today Ther Strateg (2009) 0.80
Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab. J Nephrol (2014) 0.80
Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant (2015) 0.80
Prolonged B cell depletion with rituximab is effective in treating refractory pulmonary granulomatous inflammation in granulomatosis with polyangiitis (GPA). Medicine (Baltimore) (2014) 0.79
Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. Ther Adv Musculoskelet Dis (2014) 0.78
Successful treatment of severe juvenile microscopic polyangiitis with rituximab. Clin Rheumatol (2009) 0.78
Variability of the impact of adverse events on physicians' decision making. BMC Med Inform Decis Mak (2014) 0.78
Biologic therapy for refractory scleritis: a new treatment perspective. Int Ophthalmol (2015) 0.78
Rituximab treatment for peripheral ulcerative keratitis associated with Wegener's granulomatosis. Br J Ophthalmol (2007) 0.77
B cell modulation in rheumatology. Curr Opin Pharmacol (2007) 0.77
Targeting spleen tyrosine kinase-Bruton's tyrosine kinase axis for immunologically mediated glomerulonephritis. Biomed Res Int (2014) 0.76
Rituximab in immunologic glomerular diseases. MAbs (2012) 0.76
Rituximab and leflunomide for Wegener's granulomatosis: a long-term follow-up. Rheumatol Int (2010) 0.75
Targeting the B cell in vasculitis. Pediatr Nephrol (2008) 0.75
A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis. Case Rep Rheumatol (2016) 0.75
Novel strategy for the treatment of refractory vasculitis syndrome. Ann Vasc Dis (2013) 0.75
Make the grade for Wegener's granulomatosis after kidney transplantation. NDT Plus (2009) 0.75
Anti-neutrophil cytoplasmic antibody-associated vasculitis: prevalence, treatment, and outcomes. Rheumatol Int (2017) 0.75
Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters. Clin Rheumatol (2014) 0.75
ABC of clinical haematology. Iron deficiency anaemia. BMJ (1997) 3.49
Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood (2001) 2.59
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-M0) and its clinical implications. Blood (1996) 1.95
Inhibition of autophagy abrogates tumour necrosis factor alpha induced apoptosis in human T-lymphoblastic leukaemic cells. Br J Haematol (1997) 1.87
ABC of clinical haematology. Macrocytic anaemias. BMJ (1997) 1.84
Pre-induction LDH as a prognostic factor for outcome of high dose chemotherapy (HDCT) for germ cell tumours relapsing or refractory to conventional chemotherapy. Br J Cancer (2000) 1.74
Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology (1994) 1.65
Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia. Leukemia (2005) 1.64
Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood (2001) 1.55
Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J Clin Oncol (1996) 1.54
Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. N Engl J Med (1990) 1.52
Cardiovascular involvement in thalassaemic patients with pseudoxanthoma elasticum-like skin lesions: a long-term follow-up study. Eur J Clin Invest (2002) 1.44
Better blood transfusion. BMJ (1999) 1.39
Is it refractory idiopathic thrombocytopenic purpura? Lancet (1997) 1.39
Diagnosis of acute foetal distress does not preclude banking of umbilical cord blood units. Transfus Med (2006) 1.38
Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med (1995) 1.34
High-dose intravenous IgG in adults with autoimmune thrombocytopenia. Lancet (1983) 1.34
Erythrapheresis in patients with polycythaemia secondary to hypoxic lung disease. Br Med J (Clin Res Ed) (1983) 1.23
The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia (2003) 1.21
Expression of cellular oncogenes in primary cells from human acute leukemias. Proc Natl Acad Sci U S A (1986) 1.20
Pulmonary aspergillosis in patients with leukaemia. J Clin Pathol (1990) 1.20
Intravenous ciprofloxacin in the treatment of infection in immunocompromised patients. J Antimicrob Chemother (1986) 1.17
Long-term survival in childhood acute lymphocytic leukemia in Italy. Cancer (1981) 1.16
Severe aplastic anaemia after parvovirus infection in the absence of underlying haemolytic anaemia. J Clin Pathol (1988) 1.15
T cell receptor gene rearrangements define a monoclonal T cell proliferation in patients with T cell lymphocytosis and cytopenia. Blood (1986) 1.15
The miR-17∼92 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. Leukemia (2012) 1.14
Apaf-1 protein deficiency confers resistance to cytochrome c-dependent apoptosis in human leukemic cells. Blood (2001) 1.13
Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. Curr Cancer Drug Targets (2008) 1.12
Treatment of the Guillain-Barré syndrome by plasma exchange. J Neurol Neurosurg Psychiatry (1982) 1.11
Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood (2000) 1.11
Lymphocyte subsets in subjects exposed to asbestos: changes in circulating natural killer cells. Br J Ind Med (1992) 1.10
Chronic T cell lymphocytosis: a review of 21 cases. Br J Haematol (1984) 1.10
Pathology of the liver in leukaemia and lymphoma. A study of 110 autopsies. Histopathology (1995) 1.08
CD7 expression in acute myeloid leukemia. Blood (1993) 1.07
The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia (2012) 1.07
Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant (1999) 1.05
Neurological deficit associated with Mycoplasma pneumoniae reversed by plasma exchange. Br Med J (Clin Res Ed) (1983) 1.02
von Willebrand factor release and P-selectin expression is stimulated by thrombin and trypsin but not IL-1 in cultured human endothelial cells. Thromb Haemost (1993) 1.01
Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo. J Infect Dis (1998) 1.01
Effects of cell purification methods on CD11b and L-selectin expression as well as the adherence and activation of leucocytes. J Immunol Methods (1995) 1.00
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia (2006) 1.00
Multiple myeloma and immune thrombocytopenia. Clin Lab Haematol (2000) 1.00
A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia (1997) 0.99
All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia. Leukemia (1995) 0.98
Adolescent and adult acute lymphoblastic leukemia: prognostic features and outcome of therapy. A study of 293 patients. Blood (1982) 0.98
The effect of hydroxyethyl starch and other plasma volume substitutes on endothelial cell activation; an in vitro study. Intensive Care Med (1994) 0.97
Anaplastic large cell lymphoma (CD30 +/Ki-1+): results of a prospective clinico-pathological study of 69 cases. Br J Haematol (1994) 0.97
Bax translocation is crucial for the sensitivity of leukaemic cells to etoposide-induced apoptosis. Oncogene (2001) 0.97
Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood (1994) 0.97
Myelodysplastic syndromes: recent advances. Haematologica (2001) 0.97
ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse. Br J Haematol (1997) 0.96
Leukemia cell differentiation: cellular and molecular interactions of retinoids and vitamin D. Gen Pharmacol (1999) 0.94
A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol (1994) 0.94
Detection of abnormal pretransplant clones in progenitor cells of patients who developed myelodysplasia after autologous transplantation. Blood (1999) 0.94
Mitochondrial ultracondensation, but not swelling, is involved in TNF alpha-induced apoptosis in human T-lymphoblastic leukaemic cells. Leuk Res (1997) 0.94
Interleukin-3 in hematology and oncology: current state of knowledge and future directions. Cytokines Cell Mol Ther (1999) 0.94
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood (1996) 0.93
Late multifocal gliomas in adolescents previously treated for acute lymphoblastic leukemia. Cancer (1987) 0.93
Subcellular distribution and redistribution of Bcl-2 family proteins in human leukemia cells undergoing apoptosis. Blood (1999) 0.93
Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol (2000) 0.93
Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: results of the ALL R-87 protocol. Br J Haematol (1997) 0.92
Serum immunoreactive erythropoietin in hypoxic lung disease with and without polycythaemia. Clin Sci (Lond) (1985) 0.92
Treatment of elderly patients (> or =60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia (2003) 0.92
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. Leukemia (2003) 0.92
Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol (2005) 0.92
ABC of clinical haematology. Haematological emergencies. BMJ (1997) 0.91
Pancoast's tumour due to aspergilloma. Lancet (1991) 0.91
Treatment of acute myeloid leukaemia in pregnancy. Lancet (1995) 0.91
FISH analysis for CML monitoring? Ann Hematol (1996) 0.91
Efficacy of intravenous immunoglobulin in the treatment of autoimmune hemolytic anemia: results in 73 patients. Am J Hematol (1993) 0.91
High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Br J Cancer (1999) 0.90
Second primary cancer following Hodgkin's disease: updated results of an Italian multicentric study. J Clin Oncol (1991) 0.90
Radiotherapy combined with erythropoietin for the treatment of extramedullary hematopoiesis in an alloimmunized patient with thalassemia intermedia. Ann Hematol (1996) 0.90
Unusual T cell proliferations and neutropenia in rheumatoid arthritis: comparison with classical Felty's syndrome. Scand J Haematol (1984) 0.90
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia. Leukemia (1998) 0.89
Combination chemotherapy with conservative obstetric management in the treatment of pregnant patients with acute myeloblastic leukaemia. Clin Lab Haematol (1989) 0.89
Pericardial effusion following conditioning for bone marrow transplantation in acute leukaemia. Bone Marrow Transplant (1987) 0.89
Translocation of c-myc into the immunoglobulin heavy-chain locus in human acute B-cell leukemia. A molecular analysis. EMBO J (1986) 0.89
CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. J Clin Oncol (2003) 0.88
Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia. Leukemia (1995) 0.88
A phase I clinical trial of recombinant interleukin 2 following high dose chemo-radiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer (1989) 0.88
Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985. Haematol Blood Transfus (1987) 0.88
CD44 ligation on peripheral blood polymorphonuclear cells induces interleukin-6 production. Blood (2001) 0.88
A base substitution (T-->C) in codon 29 of the alpha 2-globin gene causes alpha thalassaemia. Br J Haematol (1993) 0.88
CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance. Leukemia (2006) 0.88
Effect of fixation on quantification of the expression of leucocyte function-associated surface antigens. Cytometry (1994) 0.88
A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob Chemother (1992) 0.88